BuCE Versus BuME as Conditioning Therapy in Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2018-11-30
Target enrollment:
Participant gender:
Summary
The investigators developed a protocol comparing busulfan/cyclophosphamide/etoposide (BuCE)
and busulfan/melphalan/etoposide (BuME) regimen as a conditioning for high-dose therapy (HDT)
in the patients with high risk or relapsed Non-Hodgkin's Lymphoma (NHL).